{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-060254","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.852964+00:00","generated_at":"2026-06-13T00:56:51.790428+00:00","sec_items":["3.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Allarity adds Benjamin, Oliver, Vazzano as directors; cures Nasdaq compliance gap","bullets":["Director David Roth resigned July 21, 2023 for personal reasons; Board expanded from 5 to 7 seats.","Appointed Laura Benjamin (OncXerna CEO), Robert Oliver (ex-Otsuka America CEO), Joseph Vazzano (Abeona CFO) as independent directors effective Aug 1, 2023.","New board: 4 of 6 independent; Audit & Comp committees fully independent; expected to cure Nasdaq independence rules.","Independent directors receive $50k annual retainer plus committee fees; each gets options for 2,300 shares subject to stockholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-060254","json":"https://secwatch.observer/filing/0001213900-23-060254.json","markdown":"https://secwatch.observer/filing/0001213900-23-060254.md","text":"https://secwatch.observer/filing/0001213900-23-060254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/ea182404-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T00:56:51.790428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1487745023","claim":"Joe Vazzano was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class I Director: Mr. Joe Vazzano, whose term will expire at the Company’s 2026 annual meeting of stockholders or until his respective successors are duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b340578677","claim":"David Roth resigned as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"On July 21, 2023, the Board of the Company received the resignation of Dr. David Roth as director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c3ae1d89c8","claim":"Robert Oliver was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class III Director: Mr. Robert Oliver, whose term will expire at the Company’s 2025 annual meeting of stockholders or until his respective successors are duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ec23854882","claim":"Laura Benjamin was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class II Director: Dr. Laura Benjamin, whose term will expire at the Company’s 2024 annual meeting of stockholders or until her respective successors are duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}